下気道治療薬の世界市場レポート 2024

下気道治療薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.8%の年間複合成長率（CAGR）で483億7,000万米ドルに成長すると予想されます。 下気道治療薬の予測期間で予想される増加には、いくつかの要因が考えられます。これらには、大気汚染レベルの上昇、呼吸器疾患の増加につながる人口の高齢化、抗菌薬耐性の課題、さまざまな環境要因の影響が含まれます。この期間中に予想される主な動向には、精密医療アプローチの導入、この分野で進行中の技術革新、生物学的療法の出現、呼吸器ケアにおける遠隔医療の統合、個別化された吸入装置の開発などが含まれます。これらの動向は、ヘルスケアの進歩と個別化された革新的な治療アプローチへの焦点によって推進される、下気道治療薬の進化する情勢を総合的に反映しています。

呼吸器疾患の発生が激化しているため、今後の下気道治療薬市場は大幅に拡大する見込みです。呼吸器疾患には、肺、気管支、気管、喉頭、咽頭、鼻道などの呼吸器系に影響を及ぼすさまざまな病状が含まれます。 下気道治療薬は、これらの状態の早期特定と診断において極めて重要な役割を果たし、タイムリーな介入と管理を可能にします。この積極的なアプローチは、病気の進行を止め、感染性呼吸器疾患の蔓延を制御し、合併症の可能性を軽減するのに役立ちます。スイスに本拠を置く市民社会団体NCDアライアンスが2022年9月に報告したデータによると、肺がんは世界のがん関連死亡の主な原因となっており、年間新規感染者数220万人、死亡者数180万人と予測されています。さらに、慢性呼吸器疾患は世界中で5億5,000万人の成人に影響を及ぼし、その結果420万人が死亡し、全死亡者数の7%を占めています。したがって、呼吸器疾患の有病率のエスカレートは、下気道治療薬市場の成長を推進する主要な推進力として機能すると予想されます。

喫煙率の増加は、下気道治療薬市場の成長軌道を支える重要な原動力になると予想されます。喫煙とは、タバコやその他の物質の燃焼から生じる煙の吸入と吐き出しを指します。 下気道治療薬は、炎症の緩和、症状の軽減、病気の進行の遅らせ、気流と肺機能の強化、増悪の頻度と重症度の軽減、酸素化の改善、禁煙成功の見込みの増大に役立ちます。例えば、スイスに本部を置く政府間機関である世界保健機関の報告書によると、年間800万人以上がタバコ関連の原因で死亡しており、その中には受動喫煙にさらされている非喫煙者130万人が含まれています。その結果、喫煙率の増加が、下気道治療薬市場の拡大を促進する重要な要因として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の下気道治療薬市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 喘息
• 慢性閉塞性肺疾患
• 肺炎
• 結核
• 気管支炎
• その他
• 世界の下気道治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 抗生物質
• 非ステロイド性抗炎症薬
• 咳止め剤
• 鼻詰まり除去剤
• その他
• 世界の下気道治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域および国の分析

• 世界の下気道治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の下気道治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 下気道治療薬市場の競合情勢
• 下気道治療薬市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co. Inc.
  • AbbVie Inc.

第31章 その他の大手および革新的な企業

• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc.
• Eli Lilly and Co Ltd.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Vertex Pharmaceuticals Incorporated
• Grifols SA
• Menarini Group
• Chiesi Farmaceutici SpA
• Cipla Limited
• BioMarin Pharmaceutical Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

The lower respiratory tract constitutes the segment of the respiratory system responsible for the exchange of gases, wherein oxygen is taken in, and carbon dioxide is expelled. Lower respiratory tract therapeutics is a specialized field within medical science and clinical practice that is dedicated to the diagnosis, treatment, and management of diseases and disorders affecting the lower respiratory tract. These therapeutic interventions aim to enhance the quality of life and overall health outcomes for individuals grappling with lower respiratory tract disorders.

The primary disease types addressed by lower respiratory tract therapeutics include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis, bronchitis, and others. Asthma, for instance, is a chronic respiratory disorder characterized by inflammation of the airways, resulting in their narrowing and leading to frequent bouts of coughing, wheezing, chest tightness, and shortness of breath. Various drug classes are employed in lower respiratory tract therapeutics, including antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), cough suppressants, nasal decongestants, and others. These therapeutics are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, providing individuals with access to the necessary medications for managing lower respiratory tract conditions.

The lower respiratory tract therapeutics market research report is one of a series of new reports from The Business Research Company that provides lower respiratory tract therapeutics market statistics, including lower respiratory tract therapeutics industry global market size, regional shares, competitors with lower respiratory tract therapeutics market share, detailed lower respiratory tract therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the lower respiratory tract therapeutics industry. This lower respiratory tract therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lower respiratory tract therapeutics market size has grown strongly in recent years. It will grow from $32.91 billion in 2023 to $35.8 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth observed in the historical period in lower respiratory tract therapeutics can be attributed to several factors. These include significant discoveries in antibiotics, the implementation of vaccination programs, campaigns promoting smoking cessation, advancements in inhalation therapy, and the overall growth of healthcare infrastructure. These factors collectively contributed to improved prevention, diagnosis, and treatment of lower respiratory tract disorders during the specified historical timeframe.

The lower respiratory tract therapeutics market size is expected to see strong growth in the next few years. It will grow to $48.37 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period for lower respiratory tract therapeutics can be attributed to several factors. These include the escalation of air pollution levels, an aging population leading to increased respiratory issues, the challenge of antimicrobial resistance, and the impact of various environmental factors. Key trends expected during this period encompass the adoption of precision medicine approaches, ongoing technological innovations in the field, the emergence of biologic therapies, the integration of telehealth in respiratory care, and the development of personalized inhalation devices. These trends collectively reflect the evolving landscape of lower respiratory tract therapeutics, driven by advancements in healthcare and a focus on personalized and innovative treatment approaches.

The escalating occurrence of respiratory ailments is poised to significantly bolster the lower respiratory tract therapeutics market in the forthcoming period. Respiratory illnesses encompass a range of medical conditions impacting the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Lower respiratory tract therapeutics play a pivotal role in the early identification and diagnosis of these conditions, enabling timely intervention and management. This proactive approach aids in halting disease progression, controlling the spread of infectious respiratory diseases, and mitigating the likelihood of complications. As per data reported in September 2022 by the NCD Alliance, a civil society organization based in Switzerland, lung cancer stood as the leading cause of global cancer-related deaths, foreseeing an annual estimate of 2.2 million new cases and 1.8 million fatalities. Furthermore, chronic respiratory disorders impacted 550 million adults worldwide, resulting in 4.2 million deaths, constituting 7% of all mortalities. Thus, the escalating prevalence of respiratory diseases is set to act as a major impetus driving the growth of the lower respiratory tract therapeutics market.

The increasing prevalence of smoking is anticipated to be a key driving force behind the growth trajectory of the lower respiratory tract therapeutics market. Smoking denotes the inhalation and exhalation of smoke derived from burning tobacco or other substances. Lower respiratory tract therapeutics are instrumental in mitigating inflammation, alleviating symptoms, slowing down disease progression, enhancing airflow and lung function, reducing exacerbation frequency and severity, improving oxygenation, and augmenting the prospects of successful smoking cessation. For instance, a report from The World Health Organization, an intergovernmental organization headquartered in Switzerland, revealed that over 8 million individuals succumb to tobacco-related causes annually, including 1.3 million non-smokers exposed to second-hand smoke. Consequently, the mounting prevalence of smoking is emerging as a significant factor fueling the expansion of the lower respiratory tract therapeutics market.

Advancements in product innovations stand out as a prominent trend within the lower respiratory tract therapeutics market. Major players in this domain are actively introducing novel products to fortify their positions in the market. For instance, in 2022, AstraZeneca plc, a pharmaceutical and biotechnology company based in the UK, collaborated with Sanofi S.A., a French pharmaceutical company, to introduce Beyfortus. This medication received approval from the European Union (E.U.) as a preventive measure against respiratory syncytial virus (RSV) and lower respiratory tract illnesses in newborns and infants during their initial RSV season. Markedly, Beyfortus represents the first single-dose RSV passive vaccination targeting the general newborn population, encompassing healthy infants, full-term or preterm babies, and those with specific medical conditions.

Major players operating in the lower respiratory tract therapeutics market are concentrating on innovative offerings such as triple combination drugs tailored for COPD management to bolster their market revenues. This triple combination therapy for COPD comprises long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS) as the three primary inhaled medications. For instance, Lupin Limited, a pharmaceutical company based in India, introduced Vilfuro-G in November 2023. Vilfuro-G, available in a fixed dosage strength with once-daily dosing recommendations, is poised to significantly enhance the lives of COPD patients. This launch demonstrates Lupin's commitment to expanding its respiratory product line and providing healthcare professionals and patients with state-of-the-art treatment alternatives. Notably, Vilfuro-G stands as the only fixed-dose combination specifically formulated to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.

In June 2022, Pfizer Inc., a prominent US-based pharmaceutical and biotechnology company, successfully acquired ReViral for an undisclosed amount. Through this acquisition, Pfizer seeks to broaden its portfolio of potential treatment options, with a particular focus on sisunatovir. Sisunatovir is an orally administered inhibitor specifically designed to prevent the respiratory syncytial virus (RSV) from attaching to the host cell's membrane. ReViral Ltd., the UK-based biopharmaceutical company that Pfizer acquired, is known for its dedication to developing novel antiviral therapeutics with a focus on targeting respiratory syncytial virus.

Major companies operating in the lower respiratory tract therapeutics market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Menarini Group, Chiesi Farmaceutici S.p.A., Cipla Limited, BioMarin Pharmaceutical Inc., Mundipharma International Limited, Orion Corporation, Sunovion Pharmaceuticals Inc., Innoviva Inc., Insmed Incorporated, Vectura Group plc, Kamada Ltd., Theravance Biopharma Inc., Verona Pharma plc, Circassia Pharmaceuticals plc

North America was the largest region in the lower respiratory tract therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lower respiratory tract therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lower respiratory tract therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The lower respiratory tract therapeutics market consists of sales of beta-lactam antibiotics, macrolides, and fluoroquinolones. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lower Respiratory Tract Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lower respiratory tract therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lower respiratory tract therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lower respiratory tract therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Disease Type: Asthma; Chronic obstructive pulmonary disease; Pneumonia; Tuberculosis; Bronchitis; Other Diseases
• 2) By Drug Class: Antibiotics; Non-Steroidal Anti-Inflammatory Drug; Cough Suppressant; Nasal Decongestant; Other Drug Classes
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lower Respiratory Tract Therapeutics Market Characteristics

3. Lower Respiratory Tract Therapeutics Market Trends And Strategies

4. Lower Respiratory Tract Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Lower Respiratory Tract Therapeutics Market Size and Growth

• 5.1. Global Lower Respiratory Tract Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Lower Respiratory Tract Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Lower Respiratory Tract Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Lower Respiratory Tract Therapeutics Market Segmentation

• 6.1. Global Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Asthma
• Chronic obstructive pulmonary disease
• Pneumonia
• Tuberculosis
• Bronchitis
• Other Diseases
• 6.2. Global Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antibiotics
• Non-Steroidal Anti-Inflammatory Drug
• Cough Suppressant
• Nasal Decongestant
• Other Drug Classes
• 6.3. Global Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Lower Respiratory Tract Therapeutics Market Regional And Country Analysis

• 7.1. Global Lower Respiratory Tract Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Lower Respiratory Tract Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Lower Respiratory Tract Therapeutics Market

• 8.1. Asia-Pacific Lower Respiratory Tract Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Lower Respiratory Tract Therapeutics Market

• 9.1. China Lower Respiratory Tract Therapeutics Market Overview
• 9.2. China Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Lower Respiratory Tract Therapeutics Market

• 10.1. India Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Lower Respiratory Tract Therapeutics Market

• 11.1. Japan Lower Respiratory Tract Therapeutics Market Overview
• 11.2. Japan Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Lower Respiratory Tract Therapeutics Market

• 12.1. Australia Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Lower Respiratory Tract Therapeutics Market

• 13.1. Indonesia Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Lower Respiratory Tract Therapeutics Market

• 14.1. South Korea Lower Respiratory Tract Therapeutics Market Overview
• 14.2. South Korea Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Lower Respiratory Tract Therapeutics Market

• 15.1. Western Europe Lower Respiratory Tract Therapeutics Market Overview
• 15.2. Western Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Lower Respiratory Tract Therapeutics Market

• 16.1. UK Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Lower Respiratory Tract Therapeutics Market

• 17.1. Germany Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Lower Respiratory Tract Therapeutics Market

• 18.1. France Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Lower Respiratory Tract Therapeutics Market

• 19.1. Italy Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Lower Respiratory Tract Therapeutics Market

• 20.1. Spain Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Lower Respiratory Tract Therapeutics Market

• 21.1. Eastern Europe Lower Respiratory Tract Therapeutics Market Overview
• 21.2. Eastern Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Lower Respiratory Tract Therapeutics Market

• 22.1. Russia Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Lower Respiratory Tract Therapeutics Market

• 23.1. North America Lower Respiratory Tract Therapeutics Market Overview
• 23.2. North America Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Lower Respiratory Tract Therapeutics Market

• 24.1. USA Lower Respiratory Tract Therapeutics Market Overview
• 24.2. USA Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Lower Respiratory Tract Therapeutics Market

• 25.1. Canada Lower Respiratory Tract Therapeutics Market Overview
• 25.2. Canada Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Lower Respiratory Tract Therapeutics Market

• 26.1. South America Lower Respiratory Tract Therapeutics Market Overview
• 26.2. South America Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Lower Respiratory Tract Therapeutics Market

• 27.1. Brazil Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Lower Respiratory Tract Therapeutics Market

• 28.1. Middle East Lower Respiratory Tract Therapeutics Market Overview
• 28.2. Middle East Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Lower Respiratory Tract Therapeutics Market

• 29.1. Africa Lower Respiratory Tract Therapeutics Market Overview
• 29.2. Africa Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Lower Respiratory Tract Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Lower Respiratory Tract Therapeutics Market Competitive Landscape
• 30.2. Lower Respiratory Tract Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbVie Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Lower Respiratory Tract Therapeutics Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. GlaxoSmithKline plc.
• 31.6. Eli Lilly and Co Ltd.
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Regeneron Pharmaceuticals Inc.
• 31.10. Vertex Pharmaceuticals Incorporated
• 31.11. Grifols S.A.
• 31.12. Menarini Group
• 31.13. Chiesi Farmaceutici S.p.A.
• 31.14. Cipla Limited
• 31.15. BioMarin Pharmaceutical Inc.

32. Global Lower Respiratory Tract Therapeutics Market Competitive Benchmarking

33. Global Lower Respiratory Tract Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Lower Respiratory Tract Therapeutics Market

35. Lower Respiratory Tract Therapeutics Market Future Outlook and Potential Analysis

• 35.1 Lower Respiratory Tract Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Lower Respiratory Tract Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Lower Respiratory Tract Therapeutics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer